| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SLCO2B1 |
| Uniprot No | O94956 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 461-564aa |
| 氨基酸序列 | FFIGCSSHQIAGITHQTSAHPGLELSPSCMEACSCPLDGFNPVCDPSTRVEYITPCHAGCSSWVVQDALDNSQVFYTNCSCVVEGNPVLAGSCDSTCSHLVVPF |
| 预测分子量 | 14.7 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇与SLCO2B1重组蛋白相关的文献摘要概括：
1. **文献名称**：Functional characterization of recombinant SLCO2B1 variants and their influence on prostaglandin E2 transport
**作者**：M. Hirouchi et al.
**摘要**：研究通过表达重组SLCO2B1蛋白，分析其在不同细胞模型中对前列腺素E2(PGE2)的转运能力，发现特定基因多态性会显著降低转运活性，为个体化用药提供依据。
2. **文献名称**：Role of OATP2B1 (SLCO2B1) in the absorption of oral antihistamines using recombinant protein models
**作者**：K. Tamai et al.
**摘要**：利用重组SLCO2B1蛋白的体外实验，证实该转运体参与非索非那定等抗组胺药物的肠道吸收，并探讨抑制剂对药物生物利用度的影响。
3. **文献名称**：Recombinant SLCO2B1-mediated transport of steroid conjugates in hormone-dependent cancer cells
**作者**：J. Zhou et al.
**摘要**：通过重组蛋白表达系统，揭示SLCO2B1在乳腺癌细胞中转运脱氢表雄酮硫酸盐(DHEAS)的作用机制，提示其与激素治疗耐药性相关。
4. **文献名称**：Structural insights into SLCO2B1 through recombinant expression and cryo-EM analysis
**作者**：S. Tanaka & R. Kato
**摘要**：首次报道重组SLCO2B1蛋白的高分辨率冷冻电镜结构，阐明其底物识别和跨膜转运的分子基础，为靶向药物设计提供结构支持。
(注：以上文献信息为模拟概括，实际引用需以具体论文为准。)
SLCO2B1. also known as OATP2B1 (Organic Anion Transporting Polypeptide 2B1), is a member of the solute carrier organic anion transporter family (SLCO). Encoded by the SLCO2B1 gene located on human chromosome 11q13. this protein is a transmembrane transporter primarily expressed in tissues such as the liver, small intestine, placenta, and blood-brain barrier. It facilitates the cellular uptake of a broad range of endogenous and exogenous compounds, including hormones (e.g., thyroid hormones, estrogen conjugates), prostaglandins, and drugs like statins, fexofenadine, and certain antibiotics. As a pH-dependent transporter, SLCO2B1 plays a critical role in drug absorption, distribution, and elimination, influencing pharmacokinetics and drug-drug interactions.
Recombinant SLCO2B1 protein is engineered for in vitro studies to characterize its transport mechanisms, substrate specificity, and inhibitory profiles. It is widely used in pharmaceutical research to assess whether new drug candidates are substrates or inhibitors of SLCO2B1. which helps predict potential interactions affecting drug efficacy or toxicity. Additionally, genetic polymorphisms in SLCO2B1 have been linked to interindividual variability in drug response, prompting studies using recombinant variants to analyze functional impacts of mutations.
Emerging evidence suggests SLCO2B1 may contribute to hormone-related pathologies and cancer progression. For example, its overexpression in breast and prostate cancers has been associated with altered hormone signaling and chemoresistance. However, the precise mechanisms remain under investigation. Recombinant SLCO2B1 serves as a key tool for unraveling these roles, enabling targeted assays to explore its physiological and pathological significance. Its applications extend to developing targeted therapies and personalized medicine strategies, particularly for optimizing drug delivery and mitigating adverse effects in patients with specific SLCO2B1 genotypes.
×
